Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03210259 · ClinicalTrials.gov registry record · Phase 3
The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 259
- Enrollment target
NCT03210259 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 259 participants.
The verdict
NCT03210259, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 259 participants
- Enrollment target
Study Summary
The primary objective of the trial is to assess the PK similarity between patients receiving Humira® continuously vs those who alternate between BI 695501 and Humira®, in patients with moderate-to-severe chronic plaque psoriasis. The secondary objectives of this trial are to descriptively compare the safety, immunogenicity and efficacy profiles between patients receiving Humira® continuously vs those who alternate between BI 695501 and Humira®.
Interventions
- DRUG BI 695501
- DRUG Humira®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2017-07-10 |
| Est. Completion | 2019-04-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03210259
The ClinicalTrials.gov registry entry for NCT03210259 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 259 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BI 695501 is the first listed.
NCT03210259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03210259 about?
NCT03210259 is a clinical study titled "The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis". The primary objective of the trial is to assess the PK similarity between patients receiving Humira® continuously vs those who alternate between BI 695501 and Humira®, in patients with moderate-to-severe chronic plaque psoriasis. The secondary objectives of this trial are to descriptively compare t...
What is the current status of trial NCT03210259?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 259 participants. The study started on 2017-07-10. Estimated completion is 2019-04-16.
What interventions are being tested in trial NCT03210259?
The interventions under investigation include: BI 695501 (DRUG), Humira® (DRUG).
Who is sponsoring clinical trial NCT03210259?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.